ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL

Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regul

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the anal

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL

Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical compa

SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL

Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and Chin

Gainers Vicore Pharma Holding (NASDAQ:VCRE) stock rose 149.8% to $42.47 during Monday's after-m

Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on impro

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Cali

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 r

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Ph

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data

Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a B

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduc

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS)

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALG

Akamai Technologies Inc (NASDAQ: AKAM) rose in pre-market trading after reporting strong Q1 results

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.21) per share which beat the anal

SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALG

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A

SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A

Aligos Therapeutics, Inc. (NASDAQ: ALGS - Get Free Report) has been assigned a consensus rating of "

The agreement aims to develop and commercialize pevifoscorvir sodium for chronic hepatitis B virus (

Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical

MYSE: 280% | Myseum shares are trading higher. The company announced a rebrand to Myseum.AI. ALGS: 4

Under the terms of the agreement, Aligos will receive an upfront milestone of $25M USD and is eligib

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A

Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A

WestPark Capital initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and ann

Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lower

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS)

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.91) per share which beat the anal

SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: AL